Tumor enlargement in adrenal incidentaloma is related to glaucoma: a new prognostic feature?

• Published in: Journal of endocrinological investigation 2024-02, Vol.47 (2), p.377-387
• Main Authors: Caputo, M., Daffara, T., Ferrero, A., Romanisio, M., Monti, E., Mele, C., Zavattaro, M., Tricca, S., Siani, A., Clemente, A., Palumbo, C., De Cillà, S., Carriero, A., Volpe, A., Marzullo, P., Aimaretti, G., Prodam, F.
• Format: Article
• Language: English
• Subjects: Aldosterone; Body weight; Comorbidity; Dehydroepiandrosterone; Dehydroepiandrosterone sulfate; Endocrinology; Enlargement; Glaucoma; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Metastases; Original; Original Article; Pheochromocytoma; Renin; Risk factors; Tumors
• ISSN: 1720-8386; 0391-4097; 1720-8386
• DOI: 10.1007/s40618-023-02154-9

Purpose The uncertainty on the management of small adrenal incidentalomas (AIs) still represents a challenge in real clinical practice. Considering the lack of knowledge on risk factors implicated in tumour enlargement, the aim of this study was to identify risk factors for morphological changes during follow-up of adrenal incidentalomas (AIs). Methods We retrospectively evaluated demographic, clinical, radiological and biochemical parameters of 153 AIs (2007–2021). Patients with histological diagnosis of metastases or pheochromocytoma were excluded. To detect risk factors for tumor enlargement, diseases associated with AIs were included if their prevalence was higher than 2%. Patients were divided into two groups (A: radiological stability; B: tumor enlargement defined as > 5 mm/year in the main diameter). Results Group A: 89.5% and group B: 10.5%, mean follow-up 38.6 ± 6.9 months (range 6–240). Tumor enlargement when occurred was within 36 months of follow-up. In group B high body weight ( p